Citations

Clear

2429 citation(s) found for "Shah, SS".

Global Burden of Complex Regional Pain Syndrome in At-Risk Populations: Estimates of Prevalence From 35 Countries Between 1993 and 2023
D’Souza, Ryan S. , Klasova, Johana, Saini, Camille , Chang, Albert , Music, Stephen, Shah, Jay , Elmati, Praveen Reddy , To, Jimmy, Hussain, Nasir , D'Souza, Ryan S , Saini, Chandan, Shah, Jay D., Chitneni, Ahish , Prokop, Larry J.

Mayo Clinic

Anesthesia & Analgesia | February 11, 2025 | Volume: 141 | Issue: 6 | Pages: 1275-1285

10.1213/ane.0000000000007421 | PMID 39932867 Get It

BACKGROUND: Complex regional pain syndrome (CRPS) is a debilitating and painful condition accompanied by sensory, autonomic, trophic, and/or motor abnormalities. Although CRPS is rare in the general population, the prevalence among individuals at higher risk, particularly posttraumatic and postsurgical patients, remains unknown. This study aims to provide a benchmark that quantifies CRPS prevalence in high-risk groups, and offers insights on potential predictors of developing CRPS. METHODS: We conducted a systematic review and meta-analysis to identify studies reporting prevalence of CRPS after an inciting event (eg, fracture, surgery), specifically 12-month and 24-month prevalence (primary outcomes), as well as 3-month and 6-month prevalence (secondary outcomes). Estimates from individual studies were transformed using double-arcsine transformation, and the resulting estimates with 95% confidence interval (CI) were pooled in a meta-analysis using a random-effects model. RESULTS: We included 214 articles with data from 2491,378 participants worldwide (35 countries), of which 16,873 had CRPS. The pooled 12-month and 24-month global prevalence was 3.04% (95% CI, 2.64–3.48) and 6.46% (95% CI, 5.46–7.53), respectively. Subgroup analysis and meta-regression were performed to understand the impact of population-dependent (mechanism of injury, type of CRPS), contextual-dependent (socioeconomic status), and methodological-dependent (study design, publication year) factors. The 12-month prevalence was higher in countries with a high human development index (HDI) compared to those with a medium or very high HDI, was higher in participants with a traumatic inciting injury only versus those with surgical injury only or traumatic/surgical injury, and was higher in prospective versus retrospective studies. Meta-regression analysis showed that publication year was a significant moderator, with more recent articles reporting lower 12-month prevalence. CONCLUSIONS: This study provides a benchmark of the global prevalence of CRPS, which anesthesiologists and pain specialists can use to prioritize early diagnosis and identify those at the highest risk for CRPS.
The Success and Safety of Endoscopic Retrograde Cholangiopancreatography in Surgically Altered Gastrointestinal Anatomy
Han, Samuel , Edmundowicz, Steven A. , Attwell, Augustin , Hammad, Hazem, Wani, Sachin , Edmundowicz, Steven A , Kolb, Jennifer M. , Shah, Raj J.

Mayo Clinic

Medical Sciences | February 11, 2025 | Volume: 13 | Issue: 1 | Pages: 18

10.3390/medsci13010018 | PMID 39982243 Get It

Background/Objectives: Performing endoscopic retrograde cholangiopancreatography (ERCP) in surgically altered gastrointestinal anatomy remains challenging, frequently necessitating the use of forward-viewing endoscopes. Given the challenge in endoscope selection based on the type of altered anatomy, the aim of this study was to examine ERCP success rates by specific endoscopes for different anatomy types. Methods: This single-center retrospective study examined ERCPs performed in patients with surgically altered gastrointestinal anatomy during an 18-year period. Enteroscopy success, cannulation success, and intervention success rates were compared between the different anatomy and endoscope types. Results: This study included a total of 334 adult patients (665 total ERCPs) with altered anatomy. The pediatric colonoscope was most frequently utilized (32.2%), and the majority of procedures were performed for biliary indications. Enteroscopy success was 82.2% in Roux-en-Y gastric bypass (RYGB), 97% in Billroth II, 91.5% in Whipple, and 93.2% in Roux-en-Y hepaticojejunostomy (RYHJ). Cannulation success was 90.5% in RYGB, 90.5% in Billroth II, 83.6% in Whipple, and 90.6% in RYHJ. Intervention success was 88.2% in Billroth II, 65.1% in RYGB, 81.6% in Whipple, and 87.5% in RYHJ. In patients with RYGB and RYHJ, SBE was utilized most frequently, with rotational enteroscopy having the highest success rates. The overall adverse event rate was 5.1%, with the majority of these being mild in severity. Conclusions: This large retrospective study found ERCP with forward-viewing endoscopes to be safe and effective for a variety of surgically altered anatomy types. Despite recent advances seen with endoscopic ultrasound-guided drainage procedures, this study advocates for ERCP as the initial approach for pancreaticobiliary access in surgically altered anatomy.
Enhancing Accuracy of Operative Reports with Automated Artificial Intelligence Analysis of Surgical Video
Khanna, Abhinav, Wolf, Tamir, Frank, Igor, Krueger, Alexander , Shah, Paras , Sharma, Vidit , Gettman, Matthew T., Boorjian, Stephen A. , Asselmann, Dotan, Tollefson, Matthew K.

Mayo Clinic

Journal of the American College of Surgeons | February 7, 2025 | Volume: 240 | Issue: 5 | Pages: 739-746

10.1097/xcs.0000000000001352 | PMID 39918224 Get It

BACKGROUND: The creation of operative reports is a tedious documentation task that increases administrative burden, which is a potential driver of burnout. Additionally, operative reports are inherently subjective and may contain inaccuracies and incomplete information. Recent advances in artificial intelligence (AI) technology have enabled computer vision systems to accurately detect operative steps on surgical video. We aim to develop a platform for the automated creation of video-based AI surgical operative reports in robotic-assisted radical prostatectomy. STUDY DESIGN: An AI computer vision algorithm was used to automatically detect surgical steps. Each step detected on video was mapped to prespecified text, which was then compiled into a narrative AI operative report. The accuracy of the AI operative reports was compared with operative reports written by surgeons, using expert review of raw surgical video footage as the ground truth. RESULTS: A total of 158 cases from a tertiary referral center were included. In surgeon operative reports, 84 cases (53.2%) had at least 1 discrepancy between the operative report and surgical video. Of these, 43 cases (27.2%) had a clinically significant discrepancy based on expert video review. In AI operative reports, 46 cases (29.1%) had at least 1 discrepancy between the operative report and surgical video. Of these, 20 cases (12.7%) had a clinically significant discrepancy. Overall accuracy was higher for AI operative reports compared with surgeon operative reports (87.3% vs 72.8%, p = 0.001). CONCLUSIONS: Operative reports created by AI achieved higher accuracy than those written by surgeons. To our knowledge, this is the first report of automated video-based AI surgical documentation. Future studies are warranted to explore the potential for this novel tool to reduce documentation burden, improve operative report accuracy, promote surgical transparency, and decrease subjectivity in surgical documentation.
Executive Summary of the American Radium Society Appropriate Use Criteria for Management of Squamous Cell Carcinoma of the Cervical Esophagus
Cancer, Expert Panel Management of Cervical Esophageal, Williams, Vonetta M. , Hallemeier, Christopher L. , Shah, Pari , Anker, Christopher J. , Abood, Gerard, Akselrod, Dmitriy , Kennedy, Timothy J., Lee, Percy, Sharma, Navesh , William, Small, Russo, Suzanne , Russo, Suzanne , Cancer, Expert Panel Management of Cervical Esophageal, Hallemeier, Christopher Leigh , Jethwa, Krishan R. , Selfridge, Jennifer Eva , Berlin, Jordan D. , Kim, Ed, Lee, Percy , William, Small, Tchelebi, Leila T.

Mayo Clinic

American Journal of Clinical Oncology | February 6, 2025 | Volume: 48 | Issue: 4 | Pages: 163-179

10.1097/coc.0000000000001165 | PMID 39912327 Get It

Objectives: Cervical esophageal cancer (CEC) is an uncommon malignancy accounting for <5% of all esophageal carcinomas. Treatment of CEC varies and is adapted from established regimens used for squamous cell carcinoma (SCC) or the lower esophageal and head and neck. The present systematic review and guidelines are intended to assist treatment decision making for patients with CEC based on the available evidence. Methods: Using the Population, Intervention, Comparator, Outcome, Timing, and Study Design (PICOTS) framework, the evidence regarding treatment outcomes was assessed using Cochrane and PRISMA 2020 methodology. Eligible studies included prospective Phase II to III trials and retrospective analyses published between January 1, 2013 and February 23, 2024 in the Ovid Medline database. These references were assessed through the American Radium Society (ARS) Appropriate Use Criteria (AUC) methodology. A systematic review PRISMA 2020 checklist confirmed the completion of essential elements. RAND-UCLA consensus methodology was used by the expert panel to rate the appropriateness of the treatment options. Results: ARS AUC recommendations include (1) larynx preservation using endoscopic resection (EMR or ESD) alone for the typical case with pT1a cN0 cM0 CEC, (2) definitive CRT for the typical case with cT1bN0M0 in patients who cannot undergo endoscopic resection, (3) larynx-preserving using definitive CRT (with or without induction chemotherapy) for the typical case with nonmetastatic locally advanced CEC (advanced T-stage tumors or involved lymph nodes), with surgery reserved for those patients with incomplete response or locoregional recurrence. Conclusions: This ARS AUC summary provides guidelines for the management of SCC of the cervical esophagus provides based on available evidence. Topics that warrant further investigation include optimization of (1) patient selection; (2) multimodality therapies including chemotherapy, immunotherapy, and targeted agents; (3) radiation dose, schedule, and treatment volume; and (4) supportive care for patients with CEC. Ongoing trials continue to improve outcomes for patients with CEC.
Trends in Outpatient Radical Prostatectomy and Same-Day Discharge for Prostate Cancer: Analysis of the National Inpatient Sample and Nationwide Ambulatory Surgery Sample
Henning, Grant , Deol, Ekamjit S. , Tollefson, Matthew K. , Frank, Igor, Shah, Paras , Khanna, Abhinav, Karnes, R. Jeffrey , Boorjian, Stephen A. , Sharma, Vidit , Henning, Grant M , Vasdev, Ranveer M, Basourakos, Spyridon P. , Yang, David Y. , Vasdev, Ranveer

Mayo Clinic

Urology Practice | February 4, 2025 | Volume: 12 | Issue: 3 | Pages: 305-315

10.1097/upj.0000000000000778 | PMID 39903835 Get It

Infection‐Related Hospitalization and Incident Heart Failure: The Atherosclerosis Risk in Communities Study
Molinsky, Rebecca , Shah, Amil M. , Yuzefpolskaya, M. , Yu, Bing , Misialek, Jeffrey R. , Bohn, Bruno , Vock, David M. , MacLehose, Richard F. , Borlaug, Barry A. , Colombo, P.C. , Ndumele, Chiadi E. , Ishigami, Junichi , Matsushita, Kunihiro , Lutsey, Pamela L. , Demmer, Ryan T. , Neumark‐Sztainer, Dianne , Molinsky, Rebecca L , Shah, Amil , Yuzefpolskaya, Melana , Vock, David , Colombo, Paolo C , Borlaug, Barry A , Lutsey, Pamela L , Neumark-Sztainer, Dianne , Demmer, Ryan T

Mayo Clinic

Journal of the American Heart Association | January 30, 2025 | Volume: 14 | Issue: 3 | Pages: No page available

10.1161/jaha.123.033877 | PMID 39883116 Get It

Background The immune response to infections may become dysregulated and promote myocardial damage contributing to heart failure (HF). We examined the relationship between infection‐related hospitalization (IRH) and HF, HF with preserved ejection fraction, and HF with reduced ejection fraction. Methods and Results We studied 14 468 adults aged 45 to 64 years in the ARIC (Atherosclerosis Risk in Communities) Study who were HF free at visit 1 (1987–1989). IRH was identified using select International Classification of Diseases ( ICD ) codes in hospital discharge records and was treated as a time‐varying exposure. HF incidence was defined as the first occurrence of either a hospitalization that included an ICD, Ninth Revision ( ICD‐9 ) discharge code of 428 (428.0–428.9) among the primary or secondary diagnoses or a death certificate with an ICD‐9 code of 428 or an ICD, Tenth Revision ( ICD‐10 ) code of I50 among any of the listed diagnoses or underlying causes of death. We used multivariable‐adjusted Cox proportional hazards models to assess the association between IRH and incident HF, HF with reduced ejection fraction, and HF with preserved ejection fraction. Median follow‐up time was 27 years, 55% were women, 26% were Black, mean age at baseline was 54±6 years, 46% had an IRH, and 3565 had incident HF. Hazard ratio (HR) for incident HF events among participants who had an IRH compared with those who did not was 2.35 (95% CI, 2.19–2.52). This relationship was consistent across different types of infections. Additionally, IRH was associated with both HF with reduced ejection fraction and HF with preserved ejection fraction: 1.77 (95% CI, 1.35–2.32) and 2.97 (95% CI, 2.36–3.75), respectively. Conclusions IRH was associated with incident HF, HF with reduced ejection fraction, and HF with preserved ejection fraction. IRH might represent a modifiable risk factor for HF pathophysiology.
Corticosteroids in severe alcohol-associated hepatitis. Not so fast: A systematic review of randomized controlled trials
Shi, Michael , Pungwe, Prisca , Comer, Lauren L., Balakrishnan, Maya , Lee, Tzu‐Hao , Cholankeril, George , Patidar, Kavish R. , Flores, Avegail , Shah, Vijay H. , Bataller, Ramón , Kanwal, Fasiha , Shi, Michael A , Comer, Lauren L M , Flores, Avegail G , Asrani, Sumeet K , Kanwal, Fasiha , Hernaez, Ruben , Bataller, Ramon A , Lee, Tzu-Hao , Patidar, Kavish R , Cholankeril, George , Asrani, Sumeet K. , Arab, Juan Pablo

Mayo Clinic

Hepatology | January 28, 2025 | Volume: 82 | Issue: 5 | Pages: 1241-1255

10.1097/hep.0000000000001237 | PMID 39874480 Get It

Background and Aims: Severe alcohol-associated hepatitis (AH) is rising in incidence with a high mortality burden. While corticosteroids are recommended for eligible patients with severe AH, no guidance exists for the timing of steroid initiation, tapering regimens, and surveillance of adverse events. We aim to systematically review these variables and provide evidence-based recommendations for the inpatient and outpatient management of severe AH. Approach and Results: We performed a literature search from inception to May 30, 2024, to include clinical trials published in full form and assessed the quality of evidence using the Cochrane Risk of Bias tool. Data were collected on the timing of initiation, rate, and complications following steroid therapy, and taper regimens in the setting of severe AH. Of 28 studies that fulfilled our inclusion criteria, the median time from admission to steroid initiation was 6.5 days. The most common steroid dosing regimen was prednisolone 40 mg daily for 28 days. Twenty-five studies containing 3196 subjects reported adverse events, with exactly 50% in the steroid arm and the other half in the comparison arm. Infections, gastrointestinal bleeds, and renal impairment were the most frequently reported adverse events. Most infections occurred within the first month of the study. A 2-week steroid taper was the most frequently reported regimen. Conclusions: We recommend taking up to a week to systematically and thoroughly evaluate patients before initiating steroids, and vigilant monitoring in the first month of treatment. We also recommend the lowest possible steroid exposure with a 2-week steroid taper and close outpatient follow-up.
TP53 Mutations in Myeloproliferative Neoplasms: Context‐Dependent Evaluation of Prognostic Relevance
Tefferi, Ayalew , Abdelmagid, Maymona, Loscocco, Giuseppe Gaetano , Fathima, Saubia, Begna, Kebede H. , Al‐Kali, Aref , Foran, James M. , Palmer, Jeanne , Badar, Talha , Patnaik, Mrinal M. , Reichard, Kaaren K. , He, Rong , Zepeda‐Mendoza, Cinthya , Pardanani, Animesh , Hiwase, Devendra , Gangat, Naseema , Fathima, Saubia , Loscocco, Giuseppe Gaetano , Zepeda-Mendoza, Cinthya J , Shah, Mithun V , Orazi, Attilio , Arber, Daniel A , Pardanani, Animesh , Vannucchi, Alessandro M , Hiwase, Devendra , Gangat, Naseema , Badar, Talha , Fathima, Saubia , Shah, Meera , Orazi, Attilio , Arber, Daniel A. , Vannucchi, Alessandro M. , Guglielmelli, Paola

Mayo Clinic

American Journal of Hematology | January 28, 2025 | Volume: 100 | Issue: 4 | Pages: 552-560

10.1002/ajh.27609 | PMID 39873146 Get It

ABSTRACT The clinical relevance of TP53 mutations ( TP53 MUT ) in myeloproliferative neoplasms (MPN) and their prognostic interaction with MPN subtype designation has not been systematically studied. In the current study, 114 patients with MPN harboring TP53 MUT (VAF ≥ 2%) were evaluated for overall survival (OS), calculated from the time of TP53 MUT detection: chronic phase myelofibrosis (MF‐CP; N = 61); blast‐phase (MPN‐BP; N = 31) or accelerated‐phase (MPN‐AP; N = 16) MPN, and polycythemia vera/essential thrombocythemia (PV/ET; N = 6). Sixty‐five (57%) patients harbored International Consensus Classification (ICC)‐defined multihit TP53 MUT and 56 (49%) monosomal/complex karyotype (MK/CK). Majority of MPN‐BP (90%) and MPN‐AP (81%) while 39% of MF‐CP and none of PV/ET patients harbored multihit TP53 MUT . OS in MPN‐BP and MPN‐AP was equally dismal (median 6 vs. 4.5 months, respectively; p = 1.0), regardless of multihit configuration ( p = 0.44), while OS in TP53 MUT MPN‐BP/AP ( N = 47; median 4 months) was inferior to that of a separate cohort ( N = 49) with TP53 wild‐type MPN‐BP/AP (median 11 months; p < 0.01). OS in MF‐CP was significantly shorter with multihit versus non‐multihit TP53 MUT (median 10 vs. 35 months; HR 2.9; p < 0.01), independent of other MF‐relevant genetic risk factors, including ASXL1/SRSF2/U2AF1 mutations. Multihit TP53 MUT was also associated with inferior survival following allogeneic stem cell transplant (ASCT): median 9 months versus “not reached” in patients with ( N = 9) versus without ( N = 8) multihit TP53 MUT ( p < 0.01). The presence of multihit or non‐multihit TP53 MUT in MPN‐BP/AP or multihit TP53 MUT in MF‐CP is associated with exceptionally poor prognosis and justifies inclusion into the ICC category of “myeloid neoplasms with mutated TP53 .” By contrast, detection of non‐multihit TP53 MUT , by itself, might not endanger short‐term survival in MF‐CP, PV, or ET.